Results 151 to 160 of about 57,508 (269)

LRRK2 as a Potential Disease‐Modifying Target in Sporadic Parkinson's Disease

Movement Disorders, EarlyView.
Abstract A growing understanding of the role that leucine‐rich repeat kinase 2 (LRRK2) plays in Parkinson's disease (PD) supports continued focus on this enzyme as a therapeutic target for PD. Accumulating evidence suggests that there are phenotypic, neuropathologic, and biological similarities between sporadic PD (sPD) and familial forms in which ...
Anthony E. Lang, Robert A. Hauser, Lorraine V. Kalia, Bonnie Hersh, Zdenek Berger, Roy Llorens Arenas, Coro Paisan‐Ruiz, Kyle Fraser, Danna Jennings, Jillian H. Kluss, Sarah Huntwork‐Rodriguez, Anastasia G. Henry, J. Timothy Greenamyre   +12 more
wiley   +1 more source

α-Galactosidase A Augmentation by Non-Viral Gene Therapy: Evaluation in Fabry Disease Mice. [PDF]

Pharmaceutics, 2021
Rodríguez-Castejón J, Alarcia-Lacalle A, Gómez-Aguado I, Vicente-Pascual M, Solinís Aspiazu MÁ, Del Pozo-Rodríguez A, Rodríguez-Gascón A.   +6 more
europepmc   +1 more source

Genetic heterogeneity of α‐galactosidase in fabry's disease [PDF]

, 1972
Giovanni Romeo, Barton Childs, Barbara R. Migeon   +2 more
openalex   +1 more source

Bridging Psychological Stress and Skin Cellular Aging: Flavonoids as a Dual‐Action Therapeutic Strategy

Phytotherapy Research, EarlyView.
ABSTRACT Psychological stress (or simply “stress”) is a major contributor to chronic disease worldwide, affecting 35% of the global population, including younger generations. Furthermore, it plays a significant role in human premature aging; hence, its detrimental effects on people's health compel us to comprehend and control the ways in which ...
Marco Duarte, Sílvia Santos Pedrosa, P. Raaj Khusial, Ana Raquel Madureira   +3 more
wiley   +1 more source

α-Galactosidase a Deficiency in Fabry Disease Leads to Extensive Dysregulated Cellular Signaling Pathways in Human Podocytes. [PDF]

Int J Mol Sci, 2021
Jehn U, Bayraktar S, Pollmann S, Van Marck V, Weide T, Pavenstädt H, Brand E, Lenders M.   +7 more
europepmc   +1 more source

Fabry disease: Identification of 50 novel α-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations [PDF]

, 2006
Junaid Shabbeer, Makiko Yasuda, Stacy D. Benson, Robert J. Desnick   +3 more
openalex   +1 more source

IAP Antagonists Selectively Eliminate Therapy‐Induced Senescent Cancer Cells via TNFα‐Independent Apoptosis

Cancer Science, EarlyView.
Upon chemotherapy, a subset of cancer cells enters a senescent state, referred to as TIS. When IAP antagonists are administered, TIS cells are selectively eliminated through TNFα‐independent apoptosis. TNFα secreted by TIS cancer cells may also act in a paracrine manner to enhance extrinsic apoptosis in neighboring non‐senescent cancer cells.
Hiroaki Ochiiwa, Takeshi Wakasa, Yuki Kataoka, Koji Ando, Eiji Oki, Yoshihiko Maehara, Makoto Iimori, Hiroyuki Kitao   +7 more
wiley   +1 more source

Twenty Novel Mutations in the α-Galactosidase A Gene Causing Fabry Disease [PDF]

, 1999
Ali Kemal Topaloğlu, Grace A. Ashley, Bingzheng Tong, Junaid Shabbeer, Kenneth H. Astrin, Christine M. Eng, Robert J. Desnick   +6 more
openalex   +1 more source

Ageing‐Dependent Thyroid Hormone Receptor α Reduction Activates IP3R1‐Meditated Ca2+ Transfer in MAM and Exacerbates Skeletal Muscle Atrophy in Mice

Cell Proliferation, EarlyView.
During skeletal muscle ageing, down‐regulation of TRα expression activates IP3R1 transcriptional expression, promotes MAM calcium transport, triggers mitochondrial calcium overload and apoptosis, leading to skeletal muscle atrophy. Restoring TRα expression can improve IP3R1‐mediated mitochondrial calcium overload and apoptosis in ageing skeletal muscle
Runqing Shi, Yusheng Zhang, Gong Chen, Jiru Zhang, Jing Liu, Hao Zhu, Minne Sun, Yu Duan   +7 more
wiley   +1 more source

Human α-Galactosidase A Mutants: Priceless Tools to Develop Novel Therapies for Fabry Disease. [PDF]

Int J Mol Sci, 2021
Modrego A, Amaranto M, Godino A, Mendoza R, Barra JL, Corchero JL.   +5 more
europepmc   +1 more source